Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Colorado Springs

(FURMO-004) A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

  • Details

ClinicalTrials.gov ID: NCT05607550
Diagnosis Type: Lung Cancer
USOR Number: 22198

  • Practice Details

6031 East Woodmen Road, Suite 200
Colorado Springs, CO 80923
P: (719) 577-2555

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Colorado Springs

(FURMO-004) A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

  • Details

ClinicalTrials.gov ID: NCT05607550
Diagnosis Type: Lung Cancer
USOR Number: 22198

  • Practice Details

2312 N Nevada Ave, Suite 400
Colorado Springs, CO 80907
P: (719) 577-2555

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

(FURMO-004) A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

  • Details

ClinicalTrials.gov ID: NCT05607550
Diagnosis Type: Lung Cancer
USOR Number: 22198

  • Practice Details

4715 Arapahoe Avenue
Boulder, CO 80303
P: (303) 385-2068

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Centennial

(FURMO-004) A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

  • Details

ClinicalTrials.gov ID: NCT05607550
Diagnosis Type: Lung Cancer
USOR Number: 22198

  • Practice Details

14000 E. Arapahoe Rd. Ste. 160
Centennial, CO 80112
P: 303-805-7744

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Aurora

(FURMO-004) A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

  • Details

ClinicalTrials.gov ID: NCT05607550
Diagnosis Type: Lung Cancer
USOR Number: 22198

  • Practice Details

1700 S Potomac Street
Aurora, CO 80012
P: (303) 418-7659

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Thornton

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

  • Details

ClinicalTrials.gov ID: NCT05629585
Diagnosis Type: Breast Cancer
USOR Number: 22187

  • Practice Details

8820 Huron St
Thornton, CO 80260
P: (303) 386-7622

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Lakewood

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

  • Details

ClinicalTrials.gov ID: NCT05629585
Diagnosis Type: Breast Cancer
USOR Number: 22187

  • Practice Details

11750 W 2nd Place, Suite 160
Lakewood, CO 80228
P: (303) 430-2700

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Littleton

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

  • Details

ClinicalTrials.gov ID: NCT05629585
Diagnosis Type: Breast Cancer
USOR Number: 22187

  • Practice Details

22 W Dry Creek Circle
Littleton, CO 80120
P: (303) 730-4700

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Lone Tree

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

  • Details

ClinicalTrials.gov ID: NCT05629585
Diagnosis Type: Breast Cancer
USOR Number: 22187

  • Practice Details

10107 RidgeGate Parkway, Suite 200
Lone Tree, CO 80124
P: (303) 925-0700

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Denver

A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

  • Details

ClinicalTrials.gov ID: NCT05629585
Diagnosis Type: Breast Cancer
USOR Number: 22187

  • Practice Details

4700 E Hale Parkway, Suite 400
Denver, CO 80220
P: (303) 321-0302

More Details View Practice Page
1 2 3 4 5 6 … 40

Find a Location

With more than 2,500 physicians and over 600 treatment locations across the country, the advanced cancer care you need may be available right in your local community from a practice in The US Oncology Network. Search to see if there is a center near you.